News

Coronavirus

Preannouncment: Crowdinvesting campaign on aescuvest

In the fight against coronaviruses the team of the ImmunoLogik identified a promising lead candidate for the treatment of people infected with SARS-CoV-2.

For the funding of the next steps in the drug development of the lead candidate IML-206 the ImmunoLogik starts a new crowdinvesting campaign on aescuvest.de and moneywell.de  in the context of the #CrowdBeatsCorona alliance.

Read More

US patent for IML-106 granted

It is a great pleasure to have received the message from the USA, that the in July 2015 filed patent for IML-106 has been approved after long scrutiny by the US patent office under the patent number US 10,588,896 this March. The patent extents to the substance IML-106 (in the patent described under the former trade name as PR-619) for the treatment of retroviral infectious diseases and its sequelae, especially HIV infections and AIDS.

Read More

Cooperation contract with university hospital Erlangen extended for 2020

The ImmunoLogik and the university hospital Erlangen decided to continue their successful cooperation and agreed on an extension of the cooperation contract until September 2019.

The cooperation was and is still an important building block for the development of the innovative lead candidate IML-106 for the efficient and essential treatment of HIV patients who have exploited all available means of the modern therapy and would die due to the unavoidable outbreak of AIDS.

Read More

Cooperation contract with university hospital Erlangen extended

The ImmunoLogik and the university hospital Erlangen decided to continue their successful cooperation and agreed on an extension of the cooperation contract until September 2019.

The cooperation was and is still an important building block for the development of the innovative lead candidate IML-106 for the efficient and essential treatment of HIV patients who have exploited all available means of the modern therapy and would die due to the unavoidable outbreak of AIDS.

Read More

ImmunoLogik appears on TV science documentary

On Thursday September 13th at prime-time 8.15 p.m. the ImmunoLogik represented by Dr. Christian Setz appears on the German television broadcaster 3sat in the science documentary: Medical research on the move.

The documentary examines alternatives forms of funding of pharmaceutical developments. As one of the presented projects, Christian Setz shares his experiences with crowdfunding as he experienced it with ImmunoLogik.

Read More

Crowdfunding campaign successful

On Sunday May 13th, the ImmunoLogik team around the CEO Dr. Christian Setz and the scientific advisor Prof. Dr. Ulrich Schubert successfully finsihed their crowdinvesting campaign on aescuvest.

More than 200 investors decided to invest together over 300.000 € in the innovative development of the lead candidate IML-106 for the efficient and essential treatment of patients who have exploited all available means of the modern therapy, and who would die due to the unavoidable outbreak of AIDS.

Read More